AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Florfenicol is effective against a wide range of bacterial pathogens in animals, including both Gram-positive and Gram-negative bacteria. It is commonly used to treat respiratory infections, gastrointestinal infections, urinary tract infections, and other bacterial infections in livestock and companion animals.
Respiratory Infections: Florfenicol is often used to treat respiratory infections in animals, such as bovine respiratory disease (BRD) in cattle, swine respiratory disease complex (SRDC) in pigs, and respiratory infections in poultry.
Gastrointestinal Infections: Florfenicol may be used to treat gastrointestinal infections in animals, including bacterial enteritis and colitis.
Urinary Tract Infections: Florfenicol can be used to treat urinary tract infections in animals caused by susceptible bacteria.
Systemic Infections: Florfenicol may be prescribed for systemic bacterial infections in animals when oral or injectable administration is preferred or necessary.
Mastitis: Florfenicol may be used to treat mastitis, an inflammation of the mammary gland, in dairy cows caused by susceptible bacteria.
Ear Infections: Florfenicol is an active ingredient in veterinary products used to treat otitis externa (ear infections) in dogs.
Antibiotic Resistance: Like other antibiotics, the use of florfenicol in animals can contribute to the development of antibiotic resistance in bacteria. It is essential to use florfenicol judiciously and according to veterinary guidelines to minimize the risk of resistance.
Adverse Effects: Florfenicol is generally well-tolerated in animals when used as directed. However, like all medications, it can cause adverse effects in some individuals. Common adverse effects may include gastrointestinal disturbances, allergic reactions, and injection site reactions.
Drug Interactions: Florfenicol may interact with other medications, particularly other antibiotics or medications metabolized by the liver. It's essential for veterinarians to consider potential drug interactions when prescribing florfenicol to animals.
Pregnancy and Lactation: The safety of florfenicol use during pregnancy and lactation in animals has not been extensively studied. Veterinarians should carefully consider the potential risks and benefits before prescribing florfenicol to pregnant or lactating animals.
Withdrawal Periods: In food-producing animals, withdrawal periods must be observed to ensure that no residues of florfenicol remain in edible tissues or products such as meat, milk, or eggs beyond established regulatory limits.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Christensenella minuta | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.5 | 0.2 |
| Acne | 2 | 1.4 | 0.43 |
| ADHD | 3.7 | 2.9 | 0.28 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 1.4 | 0.5 | 1.8 |
| Allergies | 3.5 | 3.4 | 0.03 |
| Allergy to milk products | 4.1 | 4.1 | |
| Alopecia (Hair Loss) | 1.4 | 0.9 | 0.56 |
| Alzheimer's disease | 9.6 | 6.4 | 0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.3 | 1.54 |
| Ankylosing spondylitis | 3.6 | 1.6 | 1.25 |
| Anorexia Nervosa | 2.6 | 1.7 | 0.53 |
| Antiphospholipid syndrome (APS) | 0.6 | -0.6 | |
| Asthma | 1.6 | 1 | 0.6 |
| Atherosclerosis | 1.4 | 1.9 | -0.36 |
| Atrial fibrillation | 1.6 | 1.6 | 0 |
| Autism | 7.7 | 6.4 | 0.2 |
| Autoimmune Disease | 0.8 | 0.5 | 0.6 |
| Barrett esophagus cancer | 0.5 | 0.5 | |
| benign prostatic hyperplasia | 0.8 | -0.8 | |
| Bipolar Disorder | 4.7 | 3.2 | 0.47 |
| Brain Trauma | 1.4 | 1.1 | 0.27 |
| Breast Cancer | 1.1 | -1.1 | |
| Cancer (General) | 0.5 | 0.6 | -0.2 |
| Carcinoma | 2.3 | 2.2 | 0.05 |
| Celiac Disease | 2.3 | 5.4 | -1.35 |
| Cerebral Palsy | 1.3 | -1.3 | |
| Chronic Fatigue Syndrome | 3.4 | 1.1 | 2.09 |
| Chronic Kidney Disease | 2.3 | 2 | 0.15 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.2 | -1 |
| Chronic Urticaria (Hives) | 0.5 | 1.6 | -2.2 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 1.1 | -1.2 |
| Cognitive Function | 4.1 | 3.6 | 0.14 |
| Colorectal Cancer | 5.2 | 2.6 | 1 |
| Constipation | 0.5 | 0.8 | -0.6 |
| Coronary artery disease | 2.6 | 1.6 | 0.63 |
| COVID-19 | 6.7 | 5.9 | 0.14 |
| Crohn's Disease | 7.8 | 6.3 | 0.24 |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.6 | -0.6 | |
| Depression | 8.7 | 8.3 | 0.05 |
| Dermatomyositis | 2.7 | 1 | 1.7 |
| Eczema | 2.4 | 2.4 | |
| Endometriosis | 1.9 | 2 | -0.05 |
| Eosinophilic Esophagitis | 2.2 | 0.3 | 6.33 |
| Epilepsy | 5.4 | 2.5 | 1.16 |
| erectile dysfunction | 0.3 | 1.2 | -3 |
| Fibromyalgia | 1.9 | 1 | 0.9 |
| Functional constipation / chronic idiopathic constipation | 5.9 | 4 | 0.48 |
| gallstone disease (gsd) | 1.6 | 1 | 0.6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.1 | 0.18 |
| Generalized anxiety disorder | 1.5 | 3.2 | -1.13 |
| giant cell arteritis | 0.3 | 0.5 | -0.67 |
| Glioblastoma | 0.8 | -0.8 | |
| Gout | 2.7 | 1.2 | 1.25 |
| Graves' disease | 4.2 | 2.4 | 0.75 |
| Gulf War Syndrome | 1.1 | 1.7 | -0.55 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.6 | 2.3 | -0.44 |
| Heart Failure | 2.3 | 1.4 | 0.64 |
| hemorrhagic stroke | 1 | 0.8 | 0.25 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.8 | -0.8 | |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.5 | 0.6 |
| hyperglycemia | 1 | 0.5 | 1 |
| Hyperlipidemia (High Blood Fats) | 1.7 | 3.7 | -1.18 |
| hypersomnia | 0.1 | 2.2 | -21 |
| hypertension (High Blood Pressure | 5.2 | 4.5 | 0.16 |
| Hypothyroidism | 0.8 | 1.1 | -0.38 |
| Hypoxia | 0.5 | -0.5 | |
| IgA nephropathy (IgAN) | 1.3 | 1.6 | -0.23 |
| Inflammatory Bowel Disease | 6.4 | 4.6 | 0.39 |
| Insomnia | 2.5 | 1.8 | 0.39 |
| Intelligence | 1 | 1.3 | -0.3 |
| Intracranial aneurysms | 3.3 | 2 | 0.65 |
| Irritable Bowel Syndrome | 5 | 5.3 | -0.06 |
| ischemic stroke | 2.1 | 1.6 | 0.31 |
| Juvenile idiopathic arthritis | 1.6 | 1.6 | |
| Liver Cirrhosis | 4.3 | 2.7 | 0.59 |
| Long COVID | 8.7 | 9 | -0.03 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.6 | 1.3 | 0.23 |
| Lymphoma | 1 | -1 | |
| Mast Cell Issues / mastitis | 1.7 | -1.7 | |
| ME/CFS with IBS | 0.5 | 0.5 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 9.5 | 6.9 | 0.38 |
| Mood Disorders | 9.5 | 8.5 | 0.12 |
| Multiple Sclerosis | 5.7 | 3.7 | 0.54 |
| Multiple system atrophy (MSA) | 1 | 0.3 | 2.33 |
| myasthenia gravis | 0.5 | 0.5 | 0 |
| neuropathic pain | 0.5 | -0.5 | |
| Neuropathy (all types) | 1.9 | 1.7 | 0.12 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.6 | 1 | 0.6 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 5.3 | -0.47 |
| NonCeliac Gluten Sensitivity | 1.4 | 2.2 | -0.57 |
| Obesity | 9.9 | 9.7 | 0.02 |
| obsessive-compulsive disorder | 1.8 | 1.8 | 0 |
| Osteoarthritis | 1.6 | 1.4 | 0.14 |
| Osteoporosis | 2.8 | 3 | -0.07 |
| pancreatic cancer | 1.2 | 0.8 | 0.5 |
| Parkinson's Disease | 11.1 | 5.8 | 0.91 |
| Peanut Allergy | 1 | -1 | |
| Polycystic ovary syndrome | 4.6 | 4.7 | -0.02 |
| Premenstrual dysphoric disorder | 0.6 | 1.1 | -0.83 |
| primary biliary cholangitis | 0.3 | 2.2 | -6.33 |
| Primary sclerosing cholangitis | 1.7 | 2.1 | -0.24 |
| Psoriasis | 0.8 | 2.3 | -1.87 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 2.1 | 1.48 |
| Rosacea | 2.6 | 0.5 | 4.2 |
| Schizophrenia | 7.3 | 3.4 | 1.15 |
| scoliosis | 0.2 | 0.9 | -3.5 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 1 | 2.4 | -1.4 |
| Sleep Apnea | 0.9 | 2.9 | -2.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.3 | 2.3 | |
| Stress / posttraumatic stress disorder | 1.6 | 2 | -0.25 |
| Systemic Lupus Erythematosus | 2 | 4 | -1 |
| Tic Disorder | 1.1 | 0.6 | 0.83 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 4.1 | 2.9 | 0.41 |
| Type 2 Diabetes | 9.3 | 5.6 | 0.66 |
| Ulcerative colitis | 6.5 | 6.8 | -0.05 |
| Unhealthy Ageing | 1.1 | 3 | -1.73 |
| Vitiligo | 0.3 | 0.3 | 0 |
